Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sifi S P A currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 3 distinct examiners and 2 distinct art units. This distribution shows that while the company's active cases are spread across multiple examiners, they are concentrated within a limited number of technical groups at the patent office.
WEBB, WALTER E is the busiest examiner for the company, overseeing 1 pending office action. Given that there are 3 pending office actions and 3 distinct examiners, each examiner is responsible for exactly 1 case. This indicates a lack of examiner concentration, which may lead to diverse perspectives on the patentability of the company's applications within the Biotechnology & Pharmaceuticals sector.
The involvement of 2 distinct art units suggests that the 3 pending office actions fall into closely related technical categories. Practitioners should note that while WEBB, WALTER E handles 1 pending office action, the other cases are being reviewed by different individuals. Coordinating responses across 3 distinct examiners and 2 distinct art units will be necessary to ensure a cohesive prosecution approach for the company's current portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.5% | +60.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860409 | Microemulsion Pharmaceutical Composition For Treatment Of Disorders Of The Anterior Segment Of The Eye | WEBB, WALTER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782207 | EYE TOPICAL COMPOSITION CONTAINING METABOLITES OF THE FERMENTATION OF LACTOBACILLUS | FERNANDEZ, SUSAN EMILY | 44d overdue |
| 18860409 | Microemulsion Pharmaceutical Composition For Treatment Of Disorders Of The Anterior Segment Of The Eye | WEBB, WALTER E | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860409 | Microemulsion Pharmaceutical Composition For Treatment Of Disorders Of The Anterior Segment Of The Eye | WEBB, WALTER E | — | §101§102§103§112 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 17802588 | FORMULATION BASED ON POLYHEXAMETHYLENE BIGUANIDE FOR USE IN THE TREATMENT OF ACANTHAMOEBA KERATITIS AND/OR FUNGAL INFECTIONS | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 24d overdue | Pending | Aug 26, 2022 |
| 17782207 | EYE TOPICAL COMPOSITION CONTAINING METABOLITES OF THE FERMENTATION OF LACTOBACILLUS | FERNANDEZ, SUSAN EMILY | 1651 | §103 | Final Rejection | 44d overdue | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial